STAT+: FDA finalizes its guidance on apps related to drugs, pharma rejoices
Reported by STAT News · all stories from statnews.com
Editorial digest
The FDA has issued finalized regulatory recommendations concerning digital programs linked to prescription drugs. Pharmaceutical companies welcomed the completed oversight framework, which aims to clarify standards for software tools paired with medical treatments.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom10/6/2026
STAT+: FDA spells out 2027 AI guidance plans
The FDA has detailed its plans for AI guidelines in 2027.
- Trusted health newsroom10/22/2026
STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction
Virtual clinics are providing off-label GLP-1 therapies for substance use disorders before receiving formal regulatory authorization.
- Trusted health newsroom10/7/2026
STAT+: Why health AI pilots in Utah may be on a collision course with the FDA
Utah's healthcare artificial intelligence trials may conflict with federal regulatory bodies.
- Trusted health newsroom8/25/2026
STAT+: FDA promises new AI guidance, and what happened at Epic’s UGM
The FDA will issue new AI regulations; Epic's user meeting also had significant updates.
- Trusted health newsroom8/24/2026
STAT+: FDA digital health leader promises generative AI regulatory guidance is coming
FDA digital health head confirms generative AI regulatory guidelines are in development.
- Trusted health newsroom10/14/2026
STAT+: Lobbyists and trade groups fight to shape how states regulate medical AI
Industry representatives are working to influence state-level medical artificial intelligence rules.